Literature DB >> 19800103

Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.

Brody Winn1, Rosemarie Tavares, Andres Matoso, Lelia Noble, Jacqueline Fanion, Scott A Waldman, Murray B Resnick.   

Abstract

Guanylyl cyclase C, a receptor for bacterial diarrheagenic enterotoxins, is expressed selectively by intestinal epithelium and is an endogenous downstream target of CDX2. The expression of Guanylyl cyclase C is preserved throughout the adenoma/carcinoma sequence in the colorectum. Detection of Guanylyl cyclase C expression by reverse transcriptase-polymerase chain reaction is currently being validated as a technique to identify occult lymph node metastases in patients with colorectal cancer and for circulating cells in the blood for postoperative surveillance. Although Guanylyl cyclase C is widely expressed by well-differentiated colorectal cancer, its expression in poorly differentiated colorectal cancer has not been evaluated. A tissue microarray was created from 69 archival specimens including 44 poorly differentiated, 15 undifferentiated or medullary, and 10 signet ring cell colorectal carcinomas. Matched normal colonic mucosa was used as a positive control. Immunohistochemical staining for Guanylyl cyclase C and CDX2 was evaluated as positive or negative based on at least a 10% extent of staining. Of the 69 tumor samples, 75%, 47%, and 90% of the poorly differentiated, medullary, and signet ring cell tumors were positive for Guanylyl cyclase C and 75%, 40% and 90% of these subsets were positive for CDX2, respectively. There was excellent correlation between Guanylyl cyclase C and CDX2 expression on a case-per-case basis (P < .0001). There was also a statistically significant difference in the Guanylyl cyclase C staining pattern between medullary carcinomas and poorly differentiated, not otherwise specified (P = .05). Immunopositivity for Guanylyl cyclase C was greater than 95% in a separately stained microarray series of well/moderately differentiated colorectal carcinomas. In conclusion, Guanylyl cyclase C expression is lost in a quarter of poorly differentiated and half of undifferentiated colorectal carcinomas. Therefore, the utility of Guanylyl cyclase C expression as a diagnostic marker for colorectal carcinoma may be questionable in poorly differentiated colorectal neoplasms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800103      PMCID: PMC2789905          DOI: 10.1016/j.humpath.2009.07.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  23 in total

Review 1.  Detection and measurement of occult disease for the prognosis of solid tumors.

Authors:  Tracy G Lugo; Stephan Braun; Richard J Cote; Klaus Pantel; Valerie Rusch
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

2.  Guanylyl cyclase is a heat-stable enterotoxin receptor.

Authors:  S Schulz; C K Green; P S Yuen; D L Garbers
Journal:  Cell       Date:  1990-11-30       Impact factor: 41.582

3.  Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites.

Authors:  J H Lagendijk; H Mullink; P J Van Diest; G A Meijer; C J Meijer
Journal:  Hum Pathol       Date:  1998-05       Impact factor: 3.466

4.  Prognostic value of humbug gene overexpression in stage II colon cancer.

Authors:  JiYi Wang; Suzanne M de la Monte; Edmond Sabo; Sripathi Kethu; Rosemarie Tavares; Mark Branda; Lelia Simao; Jack R Wands; Murray B Resnick
Journal:  Hum Pathol       Date:  2006-10-03       Impact factor: 3.466

5.  CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.

Authors:  Robert W Werling; Hadi Yaziji; Carlos E Bacchi; Allen M Gown
Journal:  Am J Surg Pathol       Date:  2003-03       Impact factor: 6.394

6.  Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation.

Authors:  Brody Winn; Rosemarie Tavares; Jacqueline Fanion; Lelia Noble; John Gao; Edmond Sabo; Murray B Resnick
Journal:  Hum Pathol       Date:  2008-11-07       Impact factor: 3.466

7.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

8.  Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma.

Authors:  Sevgi Bakaris; Ali Cetinkaya; Fikret Ezberci; Hasan Ekerbicer
Journal:  Histol Histopathol       Date:  2008-09       Impact factor: 2.303

9.  Microsatellite instability in poorly differentiated adenocarcinomas of the colon and rectum: relationship to clinicopathological features.

Authors:  Yoshihiro Kazama; Toshiaki Watanabe; Takamitsu Kanazawa; Junichiro Tanaka; Toshiaki Tanaka; Hirokazu Nagawa
Journal:  J Clin Pathol       Date:  2007-06       Impact factor: 3.411

10.  Molecular signature detection of circulating tumor cells using a panel of selected genes.

Authors:  Annalisa Gervasoni; Rina M Monasterio Muñoz; Georg S Wengler; Anna Rizzi; Alberto Zaniboni; Ornella Parolini
Journal:  Cancer Lett       Date:  2008-02-08       Impact factor: 8.679

View more
  10 in total

1.  Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia.

Authors:  Babar Bashir; Dante J Merlino; Jeffrey A Rappaport; Esteban Gnass; Juan P Palazzo; Ying Feng; Eric R Fearon; Adam E Snook; Scott A Waldman
Journal:  Hum Pathol       Date:  2019-02-02       Impact factor: 3.466

2.  Current status of gene expression profiling to assist decision making in stage II colon cancer.

Authors:  Cheng E Chee; Neal J Meropol
Journal:  Oncologist       Date:  2014-05-28

3.  Medullary carcinoma of the colon: can the undifferentiated be differentiated?

Authors:  Anne-Marie Kanstrup Fiehn; Morten Grauslund; Anders Glenthøj; Linea Cecilie Melchior; Ben Vainer; Gro Linno Willemoe
Journal:  Virchows Arch       Date:  2014-10-23       Impact factor: 4.064

4.  A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.

Authors:  Khaldoun Almhanna; David Wright; Teresa Macarulla Mercade; Jean-Luc Van Laethem; Antonio Cubillo Gracian; Carmen Guillen-Ponce; Jason Faris; Carolina Muriel Lopez; Richard A Hubner; Johanna Bendell; Alain Bols; Jaime Feliu; Naureen Starling; Peter Enzinger; Devalingham Mahalingham; Wells Messersmith; Huyuan Yang; Adedigbo Fasanmade; Hadi Danaee; Thea Kalebic
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

5.  CDX2: Linking Cell and Patient Fates in Colon Cancer.

Authors:  Eric R Fearon; Emina H Huang
Journal:  Cell Stem Cell       Date:  2016-02-04       Impact factor: 24.633

6.  TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.

Authors:  Yung-Jue Bang; Toshimi Takano; Chia-Chi Lin; Adedigbo Fasanmade; Huyuan Yang; Hadi Danaee; Takayuki Asato; Thea Kalebic; Hui Wang; Toshihiko Doi
Journal:  Cancer Res Treat       Date:  2017-05-10       Impact factor: 4.679

7.  Predictors of Metachronous Risk Polyps After Index Colonoscopy.

Authors:  Laura Carot; Gemma Navarro; Dolores Naranjo-Hans; Mar Iglesias-Coma; Alba Dalmases; Lierni Fernández; Agustín Seoane; Andrea Buron; Beatriz Bellosillo; Xavier Bessa; Montserrat Andreu; Cristina Alvarez-Urturi
Journal:  Clin Transl Gastroenterol       Date:  2021-02-18       Impact factor: 4.488

8.  A Pilot Study of CK19, CK20 and GCC mRNA in the Peripheral Blood as a Colorectal Cancer Biomarker Panel.

Authors:  Pouria Mohammadi; Massoud Saidijam; Arastoo Kaki; Katayoon Etemadi; Nooshin Shabab; Reza Yadegarazari
Journal:  Int J Mol Cell Med       Date:  2016

9.  A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.

Authors:  Melissa Gallery; Julie Zhang; Daniel P Bradley; Pamela Brauer; Donna Cvet; Jose Estevam; Hadi Danaee; Edward Greenfield; Ping Li; Mark Manfredi; Huay-Keng Loke; Claudia Rabino; Brad Stringer; Mark Williamson; Tim Wyant; Johnny Yang; Qing Zhu; Adnan Abu-Yousif; O Petter Veiby
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

10.  Diagnostic and Prognostic Roles of CDX2 Immunohistochemical Expression in Colorectal Cancers.

Authors:  Hong Bae Choi; Jung-Soo Pyo; Soomin Son; Kyungdoc Kim; Guhyun Kang
Journal:  Diagnostics (Basel)       Date:  2022-03-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.